{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:57Z","timestamp":1787026977406,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Tumor Treating Fields (TTFields) are electric fields, delivered via wearable arrays placed on or near the tumor site, that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. As a first-in-class treatment, TTFields therapy is approved for use in newly diagnosed glioblastoma, recurrent glioblastoma, and pleural mesothelioma. Additionally, TTFields therapy is being investigated in non-small cell lung cancer (NSCLC), brain metastases from NSCLC, pancreatic cancer, ovarian cancer, hepatocellular carcinoma, and gastric adenocarcinoma. Because TTFields therapy is well tolerated and delivery is locoregional, there is low risk of additive systemic adverse events (AEs) when used with other cancer treatment modalities. The most common AE associated with TTFields therapy is mild-to-moderate skin events, which can be treated with topical agents and may be managed without significant treatment interruptions. Currently, there are no guidelines for oncologists regarding the management of TTFields therapy-related skin AEs in the thoracic region, applicable for patients with pleural mesothelioma or NSCLC. This publication aims to provide guidance on preventing, minimizing, and managing dermatologic AEs in the thoracic region to help improve patient quality of life and reduce treatment interruptions that may impact outcomes with TTFields therapy.<\/jats:p>","DOI":"10.3389\/fonc.2022.975473","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T15:50:23Z","timestamp":1672847423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region"],"prefix":"10.3389","volume":"12","author":[{"given":"Milan J.","family":"Anadkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary D.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Kalmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Ovington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda Ismail","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc Natl Acad Sci U. S. A."},{"key":"B3","unstructured":"Optune\u00ae: instructions for use for unrescetable malignant pleural mesothelioma2021"},{"key":"B4","unstructured":"Optune\u00ae: Instructions for use2019"},{"key":"B5","unstructured":"Optune\u00ae: Instructions for use (EU)2020"},{"key":"B6","doi-asserted-by":"publisher","first-page":"CT201","DOI":"10.1158\/1538-7445.Am2019-ct201","article-title":"Final results of phase II STELLAR trial: TTFields with chemotherapy in unresectable malignant pleural mesothelioma","volume":"79","author":"Ceresoli","year":"2019","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): A multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8551","article-title":"Radiological response patterns in the phase 2 STELLAR trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma (MPM)","volume":"37","author":"Grosso","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.06.025","article-title":"A phase I\/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer","volume":"81","author":"Pless","year":"2013","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pan.2018","article-title":"Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study","volume":"19","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/cancers14061568","article-title":"Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: Results of the HEPANOVA phase II study","volume":"14","author":"Gkika","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study","volume":"150","author":"Vergote","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B15","unstructured":"Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma (NCT04281576)2022"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz260.116","article-title":"1594TiP - Radiosurgery followed by Tumour Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial","volume":"30","author":"Mehta","year":"2019","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082020","article-title":"Feasibility of tumor treating fields with pemetrexed and platinum-based chemotherapy for unresectable malignant pleural mesothelioma: Single-center, real-world data","volume":"14","author":"Kutuk","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B18","article-title":"Quantitative difference of acute intraoperative expansion in various body regions","volume":"21","author":"Raposio","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13555-016-0120-y","article-title":"Acute and chronic cutaneous reactions to ionizing radiation therapy","volume":"6","author":"Bray","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B20","unstructured":"Lung cancer \u2013 non-small cell: Types of treatment2021"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4065437","article-title":"An atypical presentation of lichen planus-like reaction from pembrolizumab","volume":"2019","author":"Lee","year":"2019","journal-title":"Case Rep Dermatol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2021.01018","article-title":"Association between immune-related dermatologic adverse events and efficacy of pembrolizumab in non-small cell lung cancer patients","volume":"76","author":"Fukuoka","year":"2021","journal-title":"Pharmazie"},{"key":"B23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cllc.2021.01.006","article-title":"Cutaneous toxicities in lung cancer patients on immune checkpoint inhibitor therapy","volume":"22","author":"Keiser","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01045","article-title":"Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma","volume":"10","author":"Lacouture","year":"2020","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11060-020-03540-6","article-title":"Global post-marketing safety surveillance of tumor treating fields (TTFields) in patients with high-grade glioma in clinical practice","volume":"148","author":"Shi","year":"2020","journal-title":"J Neurooncol"},{"key":"B27","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.02017"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1017\/s1461145710001197","article-title":"Avoiding skin burns with transcranial direct current stimulation: Preliminary considerations","volume":"14","author":"Loo","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00411","article-title":"Concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: A prospective safety and feasibility study","volume":"10","author":"Bokstein","year":"2020","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.896246","article-title":"Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma","volume":"12","author":"Miller","year":"2022","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13728","article-title":"Physical properties of the photodamaged human skin dermis: Rougher collagen surface and stiffer\/harder mechanical properties","volume":"28","author":"Shao","year":"2019","journal-title":"Exp Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00759","article-title":"Environmental stressors on skin aging mechanistic insights","volume":"10","author":"Parrado","year":"2019","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1152\/physrev.00067.2017","article-title":"Wound healing: A cellular perspective","volume":"99","author":"Rodrigues","year":"2019","journal-title":"Physiol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2016.25.3.122","article-title":"The importance of hydration in wound healing: reinvigorating the clinical perspective","volume":"25","author":"Ousey","year":"2016","journal-title":"J Wound Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox168.008","article-title":"ACTR-10. Patterns of TTFields-related severe skin toxicity in GBM patients","volume":"19","author":"Lieberman","year":"2017","journal-title":"Neuro-Oncology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/ijms21041306","article-title":"Hopes and limits of adipose-derived stem cells (ADSCs) and mesenchymal stem cells (MSCs) in wound healing","volume":"21","author":"Mazini","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI130239","article-title":"Dermal adipose tissue has high plasticity and undergoes reversible dedifferentiation in mice","volume":"129","author":"Zhang","year":"2019","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.stem.2020.03.013","article-title":"Dermal adipocyte lipolysis and myofibroblast conversion are required for efficient skin repair","volume":"26","author":"Shook","year":"2020","journal-title":"Cell Stem Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.04.021","article-title":"Skinny fat cells stimulate wound healing","volume":"26","author":"Merrick","year":"2020","journal-title":"Cell Stem Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/tjps.TJPS_2_17","article-title":"Measurement of epidermis, dermis, and total skin thicknesses from six different body regions with a new ethical histometric technique","volume":"26","author":"Oltulu","year":"2018","journal-title":"Turk J Plast Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.06.008","article-title":"Topical therapies in hyperhidrosis care","volume":"32","author":"Pariser","year":"2014","journal-title":"Dermatol Clin"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2020.29.6.S20","article-title":"Medical adhesive-related skin injury","volume":"29","author":"Kelly-O'Flynn","year":"2020","journal-title":"Br J Nurs"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.12968\/bjcn.2020.25.Sup3.S12","article-title":"Moisture-associated skin damage: An overview of its diagnosis and management","volume":"25","author":"Mitchell","year":"2020","journal-title":"Br J Commun Nurs"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.03.011","article-title":"Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma","volume":"41","author":"Lacouture","year":"2014","journal-title":"Semin Oncol"},{"key":"B45","unstructured":"Topical calcineurin inhibitors factsheet2018"},{"key":"B46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3121\/cmr.2017.1363","article-title":"The role of moisturizers in addressing various kinds of dermatitis: A review","volume":"15","author":"Purnamawati","year":"2017","journal-title":"Clin Med Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/01.ASW.0000525627.54569.da","article-title":"Management of moisture-associated skin damage: A scoping review","volume":"30","author":"Woo","year":"2017","journal-title":"Adv Skin Wound Care"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/won.0000000000000513","article-title":"Peristomal medical adhesive-related skin injury: Results of an international consensus meeting","volume":"46","author":"LeBlanc","year":"2019","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12518","article-title":"Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: A randomized, multicentre, double-blinded, placebo-controlled, split-face study","volume":"29","author":"Hyun","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/won.0000000000000324","article-title":"North America wound, ostomy, and continence and enterostomal therapy nurses current ostomy care practice related to peristomal skin issues","volume":"44","author":"Colwell","year":"2017","journal-title":"J Wound Ostomy Continence Nurs"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.975473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T17:04:27Z","timestamp":1673370267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.975473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":50,"alternative-id":["10.3389\/fonc.2022.975473"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.975473","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"975473"}}